Our Commitment to Research
A Pathway to the Future
At Vertex, we are a science-led organization. Three out of five Vertex employees are dedicated to research and development (R&D) and we invest more of our operating expenses in R&D than pharmaceutical industry averages. We understand the science to help people with serious diseases.
Our scientists have spent the last 20 years doing what was once thought impossible – developing the first medicines that treat the underlying cause of cystic fibrosis (CF).
Vertex by the Numbers
![4 CF medicines in Canada](https://www.vrtx.ca/sites/default/files/styles/hww_linked_tile_line_up/public/2024-02/1_vrtx.ca_image_2.png?itok=YE6qgJXD)
![>70% of operating expenses to R&D](https://www.vrtx.ca/sites/default/files/styles/hww_linked_tile_line_up/public/2024-02/2_vrtx.ca_image_2.png?itok=LX-otaTE)
![$2.66B USD to R&D in 2022](https://www.vrtx.ca/sites/default/files/styles/hww_linked_tile_line_up/public/2024-02/3_vrtx.ca_image_2.png?itok=xVTD6UEh)
*Operating expenses are defined as R&D + Sales General & Administrative. All figures are calculated using generally accepted accounting principles.